Search

Your search keyword '"Patrizia Magnani"' showing total 2 results
Start Over Author "Patrizia Magnani" Publisher mdpi ag
2 results on '"Patrizia Magnani"'

1. Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

Author

Paola Mapelli, Samuele Ghezzo, Ana Maria Samanes Gajate, Erik Preza, Giorgio Brembilla, Vito Cucchiara, Naghia Ahmed, Carolina Bezzi, Luca Presotto, Valentino Bettinardi, Annarita Savi, Patrizia Magnani, Raffaele Menichini, Angela Coliva, Ilaria Neri, Ettore Di Gaeta, Luigi Gianolli, Massimo Freschi, Alberto Briganti, Francesco De Cobelli, Paola Scifo, and Maria Picchio

Subjects
hybrid imaging, PET/MRI, PSMA, RM2, prostate cancer, multimodal imaging, Medicine (General), R5-920
Abstract

The aim of the present study is to investigate the synergic role of 68Ga-PSMA PET/MRI and 68Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent 68Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing 68Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with 68Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, 68Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by 68Ga-PSMA, and 68Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.

Published
2021
Full Text
View/download PDF

2. Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

Author

Erik Preza, Raffaele Menichini, Valentino Bettinardi, Vito Cucchiara, Giorgio Brembilla, Maria Picchio, Massimo Freschi, Paola Scifo, Ilaria Neri, Ettore Di Gaeta, Luigi Gianolli, Francesco De Cobelli, Angela Coliva, Naghia Ahmed, Patrizia Magnani, Paola Mapelli, Luca Presotto, Carolina Bezzi, A. Savi, Samuele Ghezzo, Ana Maria Samanes Gajate, Alberto Briganti, Mapelli, P., Ghezzo, S., Samanes Gajate, A. M., Preza, E., Brembilla, G., Cucchiara, V., Ahmed, N., Bezzi, C., Presotto, L., Bettinardi, V., Savi, A., Magnani, P., Menichini, R., Coliva, A., Neri, I., Di Gaeta, E., Gianolli, L., Freschi, M., Briganti, A., De Cobelli, F., Scifo, P., Picchio, M., Mapelli, P, Ghezzo, S, Samanes Gajate, A, Preza, E, Brembilla, G, Cucchiara, V, Ahmed, N, Bezzi, C, Presotto, L, Bettinardi, V, Savi, A, Magnani, P, Menichini, R, Coliva, A, Neri, I, Di Gaeta, E, Gianolli, L, Freschi, M, Briganti, A, De Cobelli, F, Scifo, P, and Picchio, M

Subjects
Medicine (General), Quantitative imaging, medicine.medical_treatment, Clinical Biochemistry, multimodal imaging, RM2, urologic and male genital diseases, Imaging modalities, Prostate cancer, chemistry.chemical_compound, R5-920, hybrid imaging, Multimodal imaging, PSMA, Medicine, DOTA, neoplasms, business.industry, Prostatectomy, 68ga psma, Gold standard (test), medicine.disease, prostate cancer, Clinical trial, Hybrid imaging, PET/MRI, chemistry, Nuclear medicine, business
Abstract

The aim of the present study is to investigate the synergic role of 68Ga-PSMA PET/MRI and 68Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent 68Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing 68Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with 68Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, 68Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by 68Ga-PSMA, and 68Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results